NASDAQ:KNSA Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis $62.84 -0.21 (-0.33%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$62.79 -0.05 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiniksa Pharmaceuticals International Stock (NASDAQ:KNSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KNSA alerts:Sign Up Key Stats Today's Range$62.31▼$63.3950-Day Range$46.92▼$67.2952-Week Range$26.27▼$67.53Volume619,956 shsAverage Volume957,375 shsMarket Capitalization$4.83 billionP/E Ratio69.82Dividend YieldN/APrice Target$68.00Consensus RatingBuy Company Overview Kiniksa Pharmaceuticals International, Inc. is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies. The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome. Beyond Ilaris, Kiniksa’s clinical pipeline includes mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor being investigated for giant cell arteritis; remibrutinib, a selective BTK inhibitor in Phase III studies for chronic spontaneous urticaria; and pozelimab, an anti-C5 monoclonal antibody under development for rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis. Kiniksa operates globally, with commercial and development activities spanning North America, Europe and Asia under various licensing and distribution arrangements. The company is led by Founder and Chief Executive Officer John H. Johnson, who oversees a management team composed of experienced biopharmaceutical executives and scientific leaders. By combining strategic partnerships, disciplined capital allocation and a targeted R&D strategy, Kiniksa aims to deliver therapies that can transform the treatment landscape for patients with serious immune diseases.AI Generated. May Contain Errors. Read More Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreKNSA MarketRank™: Kiniksa Pharmaceuticals International scored higher than 58% of companies evaluated by MarketBeat, and ranked 391st out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingBuy Consensus RatingKiniksa Pharmaceuticals International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Kiniksa Pharmaceuticals International is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKiniksa Pharmaceuticals International has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kiniksa Pharmaceuticals International's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth40.80% Earnings GrowthEarnings for Kiniksa Pharmaceuticals International are expected to grow by 40.80% in the coming year, from $1.25 to $1.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals International is 69.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals International is 69.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.Price to Book Value per Share RatioKiniksa Pharmaceuticals International has a P/B Ratio of 8.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals International's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.21% of the float of Kiniksa Pharmaceuticals International has been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 6.85.Change versus previous monthShort interest in Kiniksa Pharmaceuticals International has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiniksa Pharmaceuticals International does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals International does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentKiniksa Pharmaceuticals International has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Kiniksa Pharmaceuticals International this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows9 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,833,228.00 in company stock.Percentage Held by Insiders51.98% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals International's insider trading history. Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNSA Stock News HeadlinesThe Goldman Sachs Group Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $75.00July 25 at 2:24 AM | americanbankingnews.comKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026July 23 at 6:47 PM | finance.yahoo.comUniversal Basic Income ALREADY existsRobert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $62.71July 17, 2026 | americanbankingnews.comKiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent GainsJuly 15, 2026 | seekingalpha.comKiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In?July 9, 2026 | finance.yahoo.comKiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comA Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41May 29, 2026 | gurufocus.comSee More Headlines KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals International's stock was trading at $41.25 at the start of the year. Since then, KNSA shares have increased by 52.3% and is now trading at $62.84. How were Kiniksa Pharmaceuticals International's earnings last quarter? Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday, April, 28th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The company's revenue for the quarter was up 55.5% on a year-over-year basis. Read the conference call transcript. When did Kiniksa Pharmaceuticals International IPO? Kiniksa Pharmaceuticals International (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals International's major shareholders? Top institutional investors of Kiniksa Pharmaceuticals International include Financial Enhancement Group LLC (0.04%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include John F Paolini, Sanj K Patel, Michael R Megna, Eben Tessari, Thomas Malley, Barry D Quart, Mark Ragosa and Ross Moat. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals International? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiniksa Pharmaceuticals International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals International investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings4/28/2026Today7/26/2026Next Earnings (Estimated)7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KNSA's financial health is in the Green zone, according to TradeSmith. KNSA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year Founded2015Price Target and Rating Average Price Target for Kiniksa Pharmaceuticals International$68.00 High Price Target$75.00 Low Price Target$60.00 Potential Upside/Downside+8.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio69.82 Forward P/E Ratio50.27 P/E GrowthN/ANet Income$59.01 million Net Margins9.69% Pretax Margin14.06% Return on Equity13.26% Return on Assets9.86% Debt Debt-to-Equity RatioN/A Current Ratio3.79 Quick Ratio3.33 Sales & Book Value Annual Sales$677.56 million Price / Sales7.14 Cash Flow$0.79 per share Price / Cash Flow79.17 Book Value$7.44 per share Price / Book8.45Miscellaneous Outstanding Shares76,940,000Free Float36,946,000Market Cap$4.83 billion OptionableOptionable Beta0.07 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:KNSA) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredThe invention Elon called the greatest in historyJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
